Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03941262 · ClinicalTrials.gov registry record · Phase 1
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
A Phase 1 study, sponsored by NKGen Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03941262 is a Phase 1 study that has completed, run by NKGen Biotech. The registered enrollment target is 27 participants.
The verdict
NCT03941262, a Phase 1 study, has completed, sponsored by NKGen Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent and in combination with avelumab or pembrolizumab, for the treatment of subjects with advanced and/or metastatic refractory cancer that has failed three or more prior lines of conventional standard of care therapy.
Interventions
- DRUG Pembrolizumab
- DRUG Avelumab
- BIOLOGICAL SNK01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2023-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03941262
The ClinicalTrials.gov registry entry for NCT03941262 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NKGen Biotech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03941262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03941262 about?
NCT03941262 is a clinical study titled "Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy". The purpose of the study is to evaluate the safety and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent and in combination with avelumab or pembrolizumab, for the treatment of subjects with advanced and/or metastatic refractory cancer that has failed three or more pr...
What is the current status of trial NCT03941262?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2019-07-15. Estimated completion is 2023-02-17.
What interventions are being tested in trial NCT03941262?
The interventions under investigation include: Pembrolizumab (DRUG), Avelumab (DRUG), SNK01 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03941262?
This trial is sponsored by NKGen Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.